Human IL-15 Alexa Fluor® 647-conjugated Antibody Summary
Accession # P40933
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
Interleukin 15 (IL-15) is a widely expressed 14 kDa cytokine that is structurally and functionally related to IL-2 (1‑3). Mature human IL‑15 shares 70% amino acid sequence identity with mouse and rat IL-15. Alternate splicing generates isoforms of IL-15 with either a long or short signal peptide (LSP or SSP), and the SSP isoform is retained intracellularly (4). IL-15 binds with high affinity to IL-15 R alpha (5). It binds with lower affinity to a complex of IL-2 R beta and the common gamma chain ( gamma c) which are also subunits of the IL-2 receptor complex (1, 6). IL-15 associates with IL-15 R alpha in the endoplasmic reticulum, and this complex is expressed on the cell surface (7, 8). The dominant mechanism of IL-15 action is known as transpresentation in which IL-15 and IL-15 R alpha are coordinately expressed on the surface of one cell and interact with complexes of IL-2 R beta / gamma c on adjacent cells (9). This enables cells to respond to IL-15 even if they do not express IL-15 R alpha (8, 10). Soluble IL-15-binding forms of IL-15 R alpha can be generated by proteolytic shedding or alternate splicing (11‑13). These molecules retain the ability to bind tightly to IL-15 and can either inhibit or augment IL-15 function (5, 12, 13). Consistent with its shared use of IL-2 receptor subunits, IL-15 induces IL-2-like effects in lymphocyte development and homeostasis (3). It is particularly important for the maintenance and activation of NK cells and CD8+ memory T cells (3). IL-15 also exerts pleiotropic effects on other hematopoietic cells and non-immune cells (2). Ligation of membrane-associated IL-15/IL-15 R alpha complexes induces reverse signaling that promotes cellular adhesion, tyrosine phosphorylation of intracellular proteins, and cytokine secretion by the IL-15/IL-15 R alpha expressing cells (14, 15).
- Grabstein, K. et al. (1994) Science 264:965.
- Budagian, V. et al. (2006) Cytokine Growth Factor Rev. 17:259.
- Ma, A. et al. (2006) Annu. Rev. Immunol. 24:657.
- Tagaya, Y. et al. (1997) Proc. Natl. Acad. Sci. USA 94:14444.
- Giri, J.G. et al. (1995) EMBO 14:3654.
- Giri, J. et al. (1994) EMBO J. 13:2822.
- Duitman, E.H. et al. (2008) Mol. Cell. Biol. 28:4851.
- Dubois, S. et al. (2002) Immunity 17:537.
- Stonier, S.W. and K.S. Schluns (2010) Immunol. Lett. 127:85.
- Burkett, P.R. et al. (2004) J. Exp. Med. 200:825.
- Budagian, V. et al. (2004) J. Biol. Chem. 279:40368.
- Mortier, E. et al. (2004) J. Immunol. 173:1681.
- Bulanova, E. et al. (2007) J. Biol. Chem. 282:13167.
- Budagian, V. et al. (2004) J. Biol. Chem. 279:42192.
- Neely, G.G. et al. (2004) J. Immunol. 172:4225.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
What concentration of LPS was used to stimulate PBMCs prior to staining with Human IL-15 Antibody, Catalog #s MAB2471 and IC2471?
PBMCs were stimulated overnight with 1 μg/mL LPS prior to staining with Human IL-15 Antibody. 3mM Monesin was added for the last 3-4 hours of stimulation.
Reviews for Human IL-15 Alexa Fluor® 647-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human IL-15 Alexa Fluor® 647-conjugated Antibody and earn rewards!
Have you used Human IL-15 Alexa Fluor® 647-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image